Last updated: February 20, 2026
What is NDC 00008-1211?
NDC 00008-1211 refers to a biosimilar product of a reference biologic, likely used for conditions such as rheumatoid arthritis, psoriasis, or other immune-related disorders. The product is marketed by Amgen as Amjevita, a biosimilar of Humira (adalimumab).
Market Landscape
Patent and Regulatory Status
Amjevita received FDA approval in September 2016 and was granted market exclusivity until January 2023[1]. The expiration of Humira patents in late 2023 opens the market for biosimilar competition.
Market Size & Penetration
Humira ranked as the top-selling drug worldwide, generating almost $20 billion in 2022[2]. Biosimilars like Amjevita aim to capture a significant share of this revenue.
Key Competitors
- Amgen's Amjevita
- Samsung Bioepis' Imraldi
- Boehringer Ingelheim's Cyltezo
- Pfizer's Abrilada
Pricing Dynamics
Initial biosimilar prices are typically 15-30% lower than the reference biologic[3]. As market penetration increases, prices tend to drop further due to competitive pressures.
Regulatory and Reimbursement Factors
Reimbursement policies in the U.S. and Europe influence biosimilar market entry and penetration. The CMS (Centers for Medicare & Medicaid Services) endorses biosimilar substitution under certain conditions, supporting lower prices.
Price Projections
Short-term (2023-2025)
- Entry Price: Estimated at 15-20% below Humira’s average wholesale price (AWP), approximately $4,000–$4,500 per year per patient[4].
- Market Share: Initially low (5-10%), constrained by brand loyalty and physician prescribing habits.
- Price Trend: Slight downward pressure due to early competition and biosimilar launches.
Medium-term (2025-2027)
- Increased Penetration: Biosimilar share increases to 30-50%.
- Average Price: Drops to 20-25% below reference, approaching $3,600–$4,000 per year.
- Market Dynamics: Entry of additional biosimilars reduces prices further; patent disputes may delay some launches.
Long-term (2027+)
- Sustainable Price Range: Stabilizes at approximately 20-25% below Humira’s current prices.
- Market Share: Biosimilars could account for 70% or more of the adalimumab market.
- Price Ceiling: Price likely to mature around $2,800–$3,200 per year per patient, reflective of ongoing competition.
Regional Variations
- United States: Prices are higher due to brand loyalty and complex reimbursement policies.
- Europe: Prices are generally lower, with discounts of up to 40% compared to the reference product.
Key Drivers & Risks
Drivers
- Patent expiry of Humira.
- Increasing acceptance of biosimilars.
- Cost pressure from payers.
Risks
- Patent litigation delays.
- Physician and patient resistance.
- Regulatory restrictions on interchangeability.
Key Takeaways
- NDC 00008-1211 (Amjevita) is positioned to gain market share post-Humira patent expiry.
- Initial biosimilar pricing will be 15-20% below Humira, with sharper declines expected over the next 3-5 years.
- Market penetration is critical; biosimilars are projected to command up to 70% of the U.S. adalimumab market.
- Prices will stabilize around 20-25% below reference biologic prices in the long term.
- Regional regulatory and reimbursement policies significantly influence pricing and market share trajectories.
FAQs
Q1: When are biosimilars like NDC 00008-1211 expected to reach peak market penetration?
A1: Approximately 2025-2027, when biosimilars could hold a majority share of the adalimumab market.
Q2: What factors could prevent biosimilar price erosion?
A2: Patent litigation, supply constraints, or physician resistance can slow adoption and limit price reductions.
Q3: How do biosimilar prices compare internationally?
A3: Prices tend to be lower in Europe, with discounts of up to 40%. US prices are higher due to market dynamics.
Q4: Are biosimilars interchangeable with the reference biologic?
A4: Regulatory approvals vary; some biosimilars are considered interchangeable, enabling automatic substitution in certain states.
Q5: What impact do payers have on biosimilar prices?
A5: Pays influence prices through formulary placement, rebate negotiations, and policies supporting biosimilar substitution, driving prices down.
References
[1] FDA. (2016). Approval notice for Amjevita.
[2] IQVIA. (2022). Global Prescription Market Data.
[3] U.S. Government Accountability Office. (2018). Biosimilar Competition.
[4] Visualized pricing data from Wholesale Acquisition Cost (WAC) and Average Wholesale Price (AWP).
Note: The above projections and analysis are based on current market trends, publicly available data, and industry reports as of early 2023.
